Correlation Between Oncopeptides and Synsam AB

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Oncopeptides and Synsam AB at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Oncopeptides and Synsam AB into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Oncopeptides AB and Synsam AB, you can compare the effects of market volatilities on Oncopeptides and Synsam AB and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Oncopeptides with a short position of Synsam AB. Check out your portfolio center. Please also check ongoing floating volatility patterns of Oncopeptides and Synsam AB.

Diversification Opportunities for Oncopeptides and Synsam AB

0.88
  Correlation Coefficient

Very poor diversification

The 3 months correlation between Oncopeptides and Synsam is 0.88. Overlapping area represents the amount of risk that can be diversified away by holding Oncopeptides AB and Synsam AB in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Synsam AB and Oncopeptides is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Oncopeptides AB are associated (or correlated) with Synsam AB. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Synsam AB has no effect on the direction of Oncopeptides i.e., Oncopeptides and Synsam AB go up and down completely randomly.

Pair Corralation between Oncopeptides and Synsam AB

Assuming the 90 days trading horizon Oncopeptides AB is expected to under-perform the Synsam AB. In addition to that, Oncopeptides is 2.8 times more volatile than Synsam AB. It trades about -0.07 of its total potential returns per unit of risk. Synsam AB is currently generating about 0.01 per unit of volatility. If you would invest  4,168  in Synsam AB on September 12, 2024 and sell it today you would earn a total of  82.00  from holding Synsam AB or generate 1.97% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthStrong
Accuracy100.0%
ValuesDaily Returns

Oncopeptides AB  vs.  Synsam AB

 Performance 
       Timeline  
Oncopeptides AB 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Oncopeptides AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in January 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.
Synsam AB 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Synsam AB has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest uncertain performance, the Stock's basic indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors.

Oncopeptides and Synsam AB Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Oncopeptides and Synsam AB

The main advantage of trading using opposite Oncopeptides and Synsam AB positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Oncopeptides position performs unexpectedly, Synsam AB can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Synsam AB will offset losses from the drop in Synsam AB's long position.
The idea behind Oncopeptides AB and Synsam AB pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.

Other Complementary Tools

Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA